These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. On the mode of action of L-dopa in Parkinson's disease. Sourkes TL Biochem Med; 1970 Feb; 3(4):321-5. PubMed ID: 4943208 [No Abstract] [Full Text] [Related]
4. L-dopa therapy in Parkinson's disease. Lipman IJ Va Med Mon (1918); 1971 May; 98(5):242-8. PubMed ID: 4931138 [No Abstract] [Full Text] [Related]
5. The effects of metopirone and adrenalectomy on the regulation of the enzymes monoamine oxidase and catechol-O-methyl transferase in different brain regions. Parvez H; Parvez S J Neurochem; 1973 Apr; 20(4):1011-20. PubMed ID: 4697866 [No Abstract] [Full Text] [Related]
6. Xenobiotic enzyme profiles and Parkinson's disease. Williams A; Steventon G; Sturman S; Waring R Neurology; 1991 May; 41(5 Suppl 2):29-32; discussion 32-3. PubMed ID: 2041591 [TBL] [Abstract][Full Text] [Related]
7. Potentiation of the L-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors. Ericsson AD J Neurol Sci; 1971 Oct; 14(2):193-7. PubMed ID: 5112212 [No Abstract] [Full Text] [Related]
8. The neurochemistry of Parkinson's disease: effect of L-dopa therapy. Lloyd KG; Davidson L; Hornykiewicz O J Pharmacol Exp Ther; 1975 Dec; 195(3):453-64. PubMed ID: 489 [TBL] [Abstract][Full Text] [Related]
9. Interactions between levodopa and other drugs: significance in the treatment of Parkinson's disease. Bianchine JR; Sunyapridakul L Drugs; 1973; 6(5):364-88. PubMed ID: 4787755 [No Abstract] [Full Text] [Related]
10. Effect of chronic administration of L-dopa on catechol-O-methyltransferase in rat tissues. Sharpless NS; Tyce GM; Owen CA Life Sci I; 1973 Feb; 12(3):97-106. PubMed ID: 4696602 [No Abstract] [Full Text] [Related]
11. Absence of response to levodopa in Parkinson's disease. Mones RJ JAMA; 1971 Aug; 217(9):1245. PubMed ID: 5109470 [No Abstract] [Full Text] [Related]
12. Symposium on levodopa in Parkinson's disease. Clinical and pharmacological aspects. Where do we go from here? Clin Pharmacol Ther; 1971; 12(2):408-16. PubMed ID: 5577487 [No Abstract] [Full Text] [Related]
13. The in vivo effect of tropolone on dopamine metabolism and the catechol-O-methyl transferase activity in the striatum of the rat. Broch OJ Acta Pharmacol Toxicol (Copenh); 1972; 31(3):217-25. PubMed ID: 5068602 [No Abstract] [Full Text] [Related]
14. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease. Muenter MD; Sharpless NS; Tyce GM Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685 [No Abstract] [Full Text] [Related]
15. Augmenting the action of levodopa. Rao SK; Vakil SD; Calne DB; Hilson A Postgrad Med J; 1972 Nov; 48(565):653-6. PubMed ID: 4568331 [TBL] [Abstract][Full Text] [Related]
16. The importance of monoamine metabolism for the pathology of the extrapyramidal system. Birkmayer W J Neurovisc Relat; 1969; 31():Suppl 9:297+. PubMed ID: 4319516 [No Abstract] [Full Text] [Related]
17. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase. Engelbrecht I; Petzer JP; Petzer A Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034 [TBL] [Abstract][Full Text] [Related]
18. Levodopa (Larodopa). For the relief of symptoms associated with Parkinson's disease and syndrome. Clin Pharmacol Ther; 1970; 11(6):921-4. PubMed ID: 4921295 [No Abstract] [Full Text] [Related]
19. Metabolic biomarkers of Parkinson's disease. Williams A; Sturman S; Steventon G; Waring R Acta Neurol Scand Suppl; 1991; 136():19-23. PubMed ID: 1801532 [TBL] [Abstract][Full Text] [Related]
20. [Role of gene polymorphism of catechol-O-methyltransferase (COMT), monoamine oxidase B (MAOB), cytochrome P450 2D6 (CYP2D6) and N-acetyltransferase 2 (NAT2) in pathogenesis of Parkinson's disease]. Białecka M; Droździk M; Podraza H Neurol Neurochir Pol; 2002; 36(1):113-21. PubMed ID: 12053603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]